Assessment of the effectiveness of tocilizumab on mortality and progression to mechanical ventilation or intensive care in patients with COVID-19 admitted to a tertiary hospital.
Andrea Pinilla RelloArantxa Magallón MartínezCristina Vicente IturbeAngel Escolano-PueyoElena Herranz BayoIrene Aguilo LafargaPublished in: European journal of hospital pharmacy : science and practice (2022)
In most patients the clinical results of tocilizumab were observed at 14 days post-administration and could benefit from earlier administration of treatment. Baseline levels of CRP, D-dimer and LDH could be prognostic factors for the evolution of the COVID-19 patient.
Keyphrases
- prognostic factors
- mechanical ventilation
- rheumatoid arthritis
- end stage renal disease
- acute respiratory distress syndrome
- coronavirus disease
- intensive care unit
- sars cov
- randomized controlled trial
- newly diagnosed
- ejection fraction
- juvenile idiopathic arthritis
- systematic review
- chronic kidney disease
- rheumatoid arthritis patients
- type diabetes
- case report
- coronary artery disease
- peritoneal dialysis
- risk factors
- cardiovascular disease
- combination therapy
- respiratory syndrome coronavirus
- smoking cessation